mcas and semaglutide Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome NW Integrative Medicine: Semaglutide Treatment

A 2022 study published in Diabetes, Obesity and Metabolism found that adults over 50 achieved clinically significant weight loss on semaglutide, with cardiovascular and metabolic risk reductions comparable to younger cohorts, though the authors noted the importance of individualized monitoring protocols for older patients given the higher baseline prevalence of comorbidities

However, some plans might cover weight loss drugs as preventive medicine before meeting the deductible

For a deeper medical comparison, see why GLP-1 medications arent substitutes for bariatric surgery

Insurance companies do not test for tirzepatide